When was Geninus founded?

Geninus was founded in 2018 and raised its 1st funding round within a year of its incorporation.

Where is Geninus located?

Geninus is headquartered in Seoul, South Korea.

How many employees does Geninus have?

As of Apr 30, 2026, the latest employee count at Geninus is 62.

Is Geninus a funded company?

Geninus is a funded company, having raised a total of $13.3M across 3 funding rounds to date. The company's 1st funding round was a $***** Angel round, raised on Oct 2018.

When was the latest funding round of Geninus?

Geninus' latest funding was a $***** Series B round on Aug 12, 2020, with participation from 5 investors.

Where does Geninus rank among its competitors?

Geninus ranks 12th amongst 60 active competitors, of which 20 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of Geninus?

Geninus' top competitors include Senti Bio, CRISPR Therapeutics and 64x Bio. Among them, Senti Bio secured the most recent funding round in May, 2026.

Geninus - 2026 Company Profile, Funding & Competitors

Geninus is a public company based in Seoul (South Korea), founded in 2018. It operates as a Developer of genomic-based disease prevention platform. Geninus has raised $13.3M in funding from investors like KTB Network, Korea Investment Partners and KB Investment. The company has 60 active competitors, including 20 funded and 13 that have exited. Its top competitors include companies like Senti Bio, CRISPR Therapeutics and 64x Bio.

Company Details

Geninus is a developer of a genomic-based disease prevention platform. It has developed a CancerScan test that detects mutations by deep sequencing based on NGS of tumor DNA extracted from cancer tissue . It supports in mutation detection and related target anticancer drugs with clinical utility through genomic analysis of cancer tissues. It also offers diet service through microbial community analysis by using genetic analysis technology. It provides single cell analysis service that analyzes single cells in the cancer genome. It helps to analyze the characteristics of individual cells and their distribution, type, and condition by cell type. It also offers services like LiquidSCAN, HealthSCAN, cancer genome analysis, microbial community genome, and many more.

Website: www.kr-geninus.com/
Email ID: *****@kr-geninus.com
Phone Number: +82 **********

Key Metrics

Founded Year

2018

Location

Seoul, South Korea

Stage

Public

Total Funding

$13.3M in 3 rounds

Latest Funding Round

Series B, Aug 12, 2020, $*****

Investors

KTB Network & 6 more

Ranked

12^th among 60 active competitors

Employee Count

62 as on Apr 30, 2026

Similar Companies

Senti Bio & 75 more

Exit Details

Public

View Geninus' full profile

Geninus got listed on Nov 08, 2021.

Click here to take a look at Geninus's IPO in detail

Geninus has raised a total funding of $13.3M over 3 rounds. Its first funding round was on Oct 2018. Its latest funding round was a Series B round on Aug 12, 2020 for $*****. 5 investors participated in its latest round. Geninus has 7 institutional investors.

Here is the list of recent funding rounds of Geninus:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 12, 2020	5999745	Series B	1506126	7380284	5431940	2851196
Dec 2018	5328645	Series A	8951644	4170238	6083815	3479715
Oct 2018	6400013	Angel	1376844	3238315	2101117	2945954

Access funding benchmarks and valuations. Sign up today!

View details of Geninus's funding rounds and investors

Geninus' employee count trend

Geninus has 62 employees as of Apr 26. Here is Geninus's employee count trend over the years:

Uncover Geninus' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Geninus include Senti Bio, CRISPR Therapeutics and 64x Bio. Here is the list of Top 10 competitors of Geninus, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
2nd	CRISPR Therapeutics 2013, Basel (Switzerland), Public	Developer of solutions for treating human genetic diseases by using genome editing technology	$127M	Celgene, Vertex Pharmaceuticals & 10 others	63/100
3rd	64x Bio 2017, San Francisco (United States), Series A	Developer of cell lines and production technologies for advanced therapies	$59.6M	Y Combinator, Fifty Years & 13 others	61/100
4th	Poseida Therapeutics 2015, San Diego (United States), Acquired	Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies	$324M	Fidelity Investments, Novartis & 12 others	60/100
5th	ADARx Pharmaceuticals 2019, San Diego (United States), Series C	Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts	$353M	BlackRock, HBM Healthcare Investments & 17 others	58/100
6th	Logomix 2019, San Carlos (United States), Series A	Provider of genome engineering platform to create artificial cells	$22.6M	UTokyo Innovation Platform, Mitsubishi UFJ Capital ... & 15 others	57/100
7th	OXGENE 2011, Oxford (United Kingdom), Acquired	Provider of a platform for mammalian cell engineering	$28.1M	Mercia, Invesco & 6 others	57/100
8th	Bota 2019, Lafayette (United States), Series B	Developer of AI-based platform for enzyme and strain engineering	$100M	Sequoia Capital China, BASF & 9 others	57/100
9th	Genprex 2009, Austin (United States), Public	Developer of therapeutics to treat cancer at molecular level	$3.11M	Inception Capital Management, TiE ScaleUp ... & 1 others	56/100
10th	Modular Genetics 2000, Woburn (United States), Series B	Developer of a proprietary, automated system for gene engineering and molecular biology	$8.9M	Boston University, National Science Foundation ... & 2 others	52/100
12th	Geninus 2018, Seoul (South Korea), Public	Developer of genomic-based disease prevention platform	$13.3M	KTB Network, KB Investment & 5 others	48/100